Metrics as of 10/17/2026, 05:51 AM (Berlin time), refresh in progress.
Heron Therapeutics Stock
Heron Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Craig Alexander Collard
- Employees
- 128
- Market cap
- $69 M
- IPO
- 26/08/1987
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This…
Heron Therapeutics stock: price history
1D
-4.1%
1W
-11.1%
1M
+13.6%
6M
-63.9%
YTD
-72.2%
1Y
-72.2%
2Y
-80.7%
5Y
-96.6%
10Y
-97.7%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~94% stronger price swings than usual
Ask the agents about Heron Therapeutics
Analyst assessment of Heron Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$6.67
MEDIAN
US$6.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
17
BUY
2
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 11/08/2026
Heron Therapeutics stock metrics
P/E
-1.93
P/B
9.95
EV/EBITDA
-7
RETURN ON EQUITY
-79.5%
NET MARGIN
-14.6%
DEBT/EQUITY
21.48
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.2%
FLOAT SHARES
146,524,213
AVG. DAILY VOLUME (30D)
2,333,526
Insider transactions (SEC)
Hensley Mark Earl
Hensley Mark Earl
Duarte Ira
Collard Craig A
Collard Craig A
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Heron Therapeutics stock
What does Heron Therapeutics do?
Heron Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Craig Alexander Collard, the company employs around 128 people.
The IPO was on 26/08/1987; the stock trades on NASDAQ under the ticker HRTX.
What do analysts say about Heron Therapeutics stock?
19 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$6.67, ranging from US$5.00 to US$9.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Heron Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 94% stronger than usual.
Does Heron Therapeutics pay a dividend?
No, Heron Therapeutics currently does not pay a dividend.
Which stocks are comparable to Heron Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Heron Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Heron Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.